- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07848009
Artificial Intelligence-Based Virtual Reality on Patient With Upper Gastrointestinal Endoscopy (Virtual)
Effect of Artificial Intelligence-Based Virtual Reality on Patient-Reported Outcomes During Upper Gastrointestinal Endoscopy: A Randomized Controlled Trial
This randomized controlled trial evaluates whether an artificial intelligence-based virtual reality (AI-VR) relaxation intervention can improve patient outcomes during upper gastrointestinal endoscopy. Patients undergoing elective upper gastrointestinal endoscopy will be randomly assigned in a 1:1 ratio to either an AI-VR intervention group or a routine-care control group. Participants in the intervention group will receive a 10-15-minute AI-VR relaxation session immediately before the endoscopy, while participants in the control group will receive routine care. The study will assess patients' anxiety, pain perception, physiological parameters, and satisfaction in relation to the endoscopy procedure. The findings will help determine whether AI-VR can improve patient comfort and the overall endoscopy experience.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Upper gastrointestinal endoscopy is an important diagnostic and therapeutic procedure; however, patients may experience anxiety, pain, discomfort, and physiological changes before and during the procedure. These experiences may negatively affect patient comfort and satisfaction. This study was designed to evaluate the effect of an artificial intelligence-based virtual reality (AI-VR) relaxation intervention on patient-reported and physiological outcomes among patients undergoing elective upper gastrointestinal endoscopy.
This study uses a randomized controlled trial design. Eligible patients undergoing elective upper gastrointestinal endoscopy will be randomly assigned in a 1:1 ratio to either an intervention group or a routine-care control group. The intervention group will receive a 10-15-minute AI-VR relaxation session immediately before undergoing upper gastrointestinal endoscopy. The control group will receive routine care according to the usual clinical practice.
The AI-VR intervention is intended to provide a relaxation experience before the endoscopic procedure. Patient outcomes will be assessed using validated measures of anxiety and pain, together with physiological parameters and patient satisfaction. Anxiety will be assessed using the State-Trait Anxiety Inventory (STAI), pain perception will be assessed using the Visual Analog Scale (VAS), and patient satisfaction will be assessed using the Patient Satisfaction Questionnaire (PSQ). Physiological parameters will also be assessed at the prespecified assessment time points.
The primary purpose of the study is to determine whether the AI-VR intervention improves patient outcomes during upper gastrointestinal endoscopy compared with routine care. Outcomes of interest include anxiety level, pain perception, physiological responses, and patient satisfaction.
Randomization will be performed using a computer-generated random sequence. Allocation concealment will be maintained using sequentially numbered, opaque, sealed envelopes. Eligible participants will be enrolled after confirmation of eligibility and informed consent and will then be assigned to their respective study groups according to the concealed allocation sequence.
Data will be analyzed using IBM SPSS Statistics version 26.0. Appropriate statistical tests will be used to compare outcomes between the intervention and control groups and to examine relationships among anxiety, pain, satisfaction, and other study variables.
The study is intended to provide evidence regarding the potential role of AI-based virtual reality as a non-pharmacological intervention for reducing anxiety and discomfort and improving physiological responses and satisfaction among patients undergoing upper gastrointestinal endoscopy.
Typ studie
Zápis (Aktuální)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
-
Amman, Jordán, 00000
- Al zaytoonah University
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria
Participants will be eligible for inclusion if they:
- Are within the prespecified age range for the study ([insert minimum and maximum age
- Are scheduled to undergo elective upper gastrointestinal endoscopy.
- Are able to understand the study procedures and communicate effectively.
- Are willing to participate in the study and provide informed consent.
Exclusion Criteria
Participants will be excluded if they:
- Have a condition that prevents them from safely participating in the virtual reality intervention.
- Have significant visual, auditory, cognitive, or neurological impairment that would interfere with the use of the virtual reality intervention or completion of the study assessments.
- Have previously participated in this study.
- Are unable or unwilling to provide informed consent.
- Require an urgent or emergency upper gastrointestinal endoscopy.
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Prevence
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: AI-Based Virtual Reality Group
Artificial Intelligence-Based Virtual Reality Relaxation |
Artificial Intelligence-Based Virtual Reality Relaxation |
|
Žádný zásah: Routine Care Control Group
non |
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Patient Anxiety During Upper Gastrointestinal Endoscopy
Časové okno: Anxiety (STAI) Baseline (pre-intervention) and immediately after the endoscopy procedure Pain intensity (VAS) Immediately after the endoscopy procedure Patient satisfaction (PSQ) Immediately after the endoscopy procedure Physiological parameters
|
Patient anxiety will be assessed using the State-Trait Anxiety Inventory (STAI). Anxiety scores will be compared between the artificial intelligence-based virtual reality intervention group and the routine-care control group to evaluate the effect of the intervention on patient anxiety during upper gastrointestinal endoscopy. The STAI consists of 20 items for assessing state anxiety, with total scores ranging from 20 to 80; higher scores indicate greater anxiety. |
Anxiety (STAI) Baseline (pre-intervention) and immediately after the endoscopy procedure Pain intensity (VAS) Immediately after the endoscopy procedure Patient satisfaction (PSQ) Immediately after the endoscopy procedure Physiological parameters
|
Spolupracovníci a vyšetřovatelé
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další identifikační čísla studie
- 1000/4/3/196/26
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Individual participant data will not be shared because the study did not establish a data-sharing arrangement for individual-level participant data. The data contain potentially identifiable participant information and will be retained securely by the research team in accordance with applicable ethical and institutional requirements. De-identified aggregate results will be reported in publications arising from the study.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .